Alzheimer’s consortium The Consortium is growing! As of June 2017, there are over 70 people registered on the mailing list representing approximately 51 companies. Please continue to introduce new members and/or companies that may be interested and make suggestions for ideas and events for the AABC to better serve its membership. For future issues of this Newsletter please contact April Ross, aqross@alz.org with the information you would like to include.
For those of you not familiar with the AABC, we encourage you to get involved in 2017/ 2018 by attending one of our events. Please email Charles Stacey (cstacey@accerapharma.com), Kira Sheinerman (ksheinerman@diamirbio.com) or Jim Hendrix (jhendrix@alz.org) to be added to the membership list mailing list.
Mission of the AABC
The mission of the AABC is to advance Alzheimer’s disease research and innovation in small/medium-sized biotechnology, diagnostics, medical device, and contract research organizations.
The AABC works to achieve their mission by working in areas of common interest in a pre-competitive space to advance both the field of Alzheimer’s research and the member company’s goals. The AABC member companies provide leadership and direction to the organizations areas of focus that include but are not limited to: Collaborations, Recognition & Visibility and Knowledge and Information Sharing.
News from AABC members and growth AD companies
ProMIS Neurosciences, Inc.
May 24, 2017- ProMIS Neurosciences, Inc., a biotech company focused on the discovery and development of precision treatments for neurodegenerative diseases, designated PMN350, a mAB that targets prion-like forms of amyloid-beta oligomers (AβO), its second lead product for Alzheimer’s disease. Read more.
May 25, 2017- Dr. Neil Cashman, CSO and Co-Founder, presented Epitope Identification of Toxic Propagating Strains of Aβ Oligomers at PRION 2017 International Conference. His presentation focused on the company’s propriety discovery engine to identify epitopes on toxic prion-like forms of Amyloid beta oligomers. Read more.
June 6, 2017- ProMIS Neurosciences, Inc., appoints internationally renowned neurologist William C. Mobley, MD, PhD, to the Company’s Scientific Advisory Board. Read more.
May 31, 2017- ProMIS Neurosciences, Inc., identified a novel therapeutic epitope target on misfolded TDP43, a key player in ALS and Dementia. Read more.